TetraLogic Pharma Raises $32 Million
TetraLogic Pharmaceuticals, a Malvern, Penn.-based developer of small molecule drugs to treat cancer, has raised $32 million in Series C funding. Clarus Ventures led the round, and was joined by Hatteras Venture Partners and return backers Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group.
11 August 2010•3 mins read
